Orladeyo (Berotralstat Hydrochloride) Patent Expiration, LOE Window & CMS Spending
Orladeyo (Berotralstat Hydrochloride) by Biocryst: FDA Orange Book core substance LOE 2040-05-01, 0 AB generics, $131.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Biocryst |
| FDA Application & Pathway | N214094 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2040-05-01 |
| Last Listed Patent or Exclusivity Date | 2040-05-01 |
| Orange Book Patents (*PED Extensions) | 32 patents (16 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $131.0M |
| 2024 Medicare Part D Spend | $77.9M |
| 2024 Medicaid Spend | $53.1M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 20.2% 2-yr change) |